Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
885
datasets available to search
ShareScore release 0.9.0
Dataset results
885 results for “cyclophosphamide”
Dataset related to: Add-On Cyclic Angiotensin-(1-7) with Cyclophosphamide Arrests Progressive Kidney Disease in Rats with ANCA Associated Glomerulonephritis
<p>The files contain all the dataset included in the manuscript divided by figures.</p> <p> </p> <p>Abstract: Rapidly progressive crescentic glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies (ANCA-GN) is a major cause of renal failure. Current immunosuppressive therapies are associated with severe side effects, intensifying the need for new therapeutic strategies. The activation of Mas receptor/Angiotensin-(1-7) axis exerted renoprotection in chronic kidney disease.<br> Here, we investigated the effect of adding the lanthionine-stabilized cyclic form of angiotensin-1-7 [cAng-(1-7)] to cyclophosphamide in a rat model of ANCA-GN. At the onset of proteinuria,Wistar Kyoto rats with ANCA-GN received vehicle or a single bolus of cyclophosphamide, with or without daily cAng-(1-7). Treatment with cAng-(1-7) plus cyclophosphamide reduced proteinuria by 85% vs. vehicle, and by 60% vs. cyclophosphamide, and dramatically limited glomerular crescents to less than 10%. The addition of cAng-(1-7) to cyclophosphamide protected against glomerular inflammation and endothelial rarefaction and restored the normal distribution of parietal epithelial cells. Ultrastructural analysis revealed a preserved GBM, glomerular endothelium and podocyte structure, demonstrating that combination therapy provided an additional layer of renoprotection. This study demonstrates that adding cAng-(1-7) to a partially effective dose of cyclophosphamide arrests the progression of renal disease in rats with ANCA-GN, suggesting that cAng-(1-7) could be a novel clinical approach for sparing immunosuppressants.</p>
Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia
ClinicalTrials.gov study NCT00824265. IPD Sharing: UNDECIDED. Countries: 18. Publications: 3.
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
ClinicalTrials.gov study NCT04503616. IPD Sharing: YES. Countries: 1. Publications: 1.
Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma
ClinicalTrials.gov study NCT00033293. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
ClinicalTrials.gov study NCT00121134. IPD Sharing: Not stated. Countries: 1. Publications: 1.
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
ClinicalTrials.gov study NCT00070564. IPD Sharing: Not stated. Countries: 3. Publications: 3.
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
ClinicalTrials.gov study NCT03680092. IPD Sharing: NO. Countries: 1. Publications: 1.
Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
ClinicalTrials.gov study NCT02853318. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
ClinicalTrials.gov study NCT01427881. IPD Sharing: Not stated. Countries: 1. Publications: 1.
BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance
ClinicalTrials.gov study NCT02029638. IPD Sharing: Not stated. Countries: 1. Publications: 1.
High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma
ClinicalTrials.gov study NCT02597062. IPD Sharing: NO. Countries: 1. Publications: 2.
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
ClinicalTrials.gov study NCT02120157. IPD Sharing: NO. Countries: 2. Publications: 1.
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
ClinicalTrials.gov study NCT01024010. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
ClinicalTrials.gov study NCT00281918. IPD Sharing: Not stated. Countries: 11. Publications: 11.
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Mela
ClinicalTrials.gov study NCT00096382. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
ClinicalTrials.gov study NCT01362790. IPD Sharing: NO. Countries: 1. Publications: 3.
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follic
ClinicalTrials.gov study NCT02596971. IPD Sharing: Not stated. Countries: 3. Publications: 2.
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
ClinicalTrials.gov study NCT00278538. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
ClinicalTrials.gov study NCT04896658. IPD Sharing: NO. Countries: 1. Publications: 17.
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
ClinicalTrials.gov study NCT01963481. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.